Abbvie Inc.

Abbott Laboratories Corporation

Abbvie Deutschland Gmbh and Co Kg

Dominique Bonafoux

Anil Vasudevan

Adrian Hobson

Wilfried Hornberger

Helmut Mack

Kristine E Frank

Michael M Friedman

Daryl Richard Sauer

Michael Z Hoemann

Ryan G Keddy

Nicole Teusch

Lu Wang

Heather M Davis

Michael F Jarvis

Shuhui Chen

George S Sheppard

Wentao Wu

David J Calderwood

Bernhard K Mueller

Martine Barth

Maria A Argiriadi

Jianfei Wang

Noel S Wilson

Eric C Breinlinger

Kelly Mullen

Dawn M George

Augustine Osuma

Andrew Burchat

Xiangdong Xu

Grier A Wallace

Didier Thomas

Raymond Huntley

Zhi Wang

Xiaoyun Wu

Gagandeep K Somal

Fabrice Guillier

Ping Ding

Steven Lewis Swann, Jr

J Martin Herold

Dominique Potin

Stacy A Van Epps

Jennifer Van Camp

Bernhard K Muller

Steve Swann, Jr

Jeremy Edmunds

Linlin Dai

Bernhard K MÜLLER

Ryan Keddy

Adrian Donald Hobson

The invention provides compounds of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.

Primary carboxamides as BTK inhibitors

The invention provides a compound of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.

Substituted 2,10-dihydro-9-oxa-1,2,4A-triazaphenanthren-3-ones and uses thereof

The present invention relates to novel 4-(4-pyridyl)-benzamides of the formula (I). The compounds I possess valuable therapeutic properties and are suitable, in particular, for treating diseases that respond to modulation of Rho kinases (ROCKs). Rand Rare, independently of each other, hydrogen, hydroxy, cyano, C-C-alkyl, C-C-haloalkyl, C-C-alkoxy or C-C-haloalkoxy; R, R, Rand Rare, independently of each other, hydrogen, hydroxy, halogen, cyano, C-C-alkyl, C-C-haloalkyl, C-C-alkoxy, C-C-haloalkoxy, amino, C-C-alkylamino or di-(C-C-alkyl)-amino; Ris hydrogen, C-C-alkyl, C-C-haloalkyl, aryl or aryl-C-C-alkyl; Ris a group of the formula &#x2014;X&#x2014;W, where X is a single bond, C-C-alkylene or C-C-alkylene-O&#x2014;, where the alkylene group in the three last-mentioned radicals may be linear or branched and may be partly or fully halogenated and/or may be substituted by a hydroxyl group and/or may be interrupted by an oxygen atom; and W is a cyclic radical selected from phenyl and a 5- or 6-membered saturated, partly unsaturated or aromatic heterocyclic ring which contains as ring members 1, 2 or 3 heteroatoms selected from O, S and N and optionally 1 or 2 carbonyl groups; Ris a group of the formula &#x2014;Y&#x2014;Z, where Z is hydrogen, halogen, OR, NRR, S(O)&#x2014;R, phenyl which may carry 1, 2, 3 or 4 substituents Ror a 5- or 6-membered saturated, partly unsaturated or aromatic heterocyclic ring; and Y is linear or branched CC-alkylene which may be partly or fully halogenated and/or may be substituted by a hydroxyl group and/or a phenyl ring; or, in case Z is phenyl or the 5- or 6-membered heterocyclic ring as defined above, Y can also be a single bond. 

4-(4-pyridinyl)-benzamides and their use as rock activity modulators

The present invention is directed to novel compounds of formula (I) wherein the variables are defined as herein. The compounds of formula (I) are useful as kinase inhibitors and as such would be useful in treating certain conditions and diseases, especially inflammatory conditions and diseases and proliferative disorders and conditions, for example, cancers.

Triazolopyridazines

The present invention is directed to novel compounds of Formula (I) wherein the variables are defined as herein. The compounds of Formula (I) are useful as CRTH2 antagonists and as such would be useful in treating certain conditions and diseases, especially asthma, allergic asthma, allergic inflammation, rhinitis, allergic rhinitis or atopic dermatitis.

Thienopyrroles and pyrrolothiazoles as new therapeutic agents

Growing community of inventors

Winthrop, MA, United States of America

Dominique Bonafoux